Bridge Medical Consulting Ltd

Bridge Medical Consulting Ltd is a healthcare consulting firm specializing in transforming clinical evidence into actionable insights for the biopharmaceutical sector, enhancing patient outcomes through integrated evidence services. Bridge Medical Consulting Ltd, founded in 2011, is headquartered in London, UK. The company focuses on evidence and outcomes research for the biopharmaceutical industry, providing tailored solutions for stakeholders. Paul Gandhi is the founder and CEO, leading the firm through its initial establishment and ongoing operations.

The company has completed one investment deal, with the most recent deal occurring on February 2, 2026. Bridge Medical specializes in evidence and outcomes research, providing integrated services that transform clinical evidence into actionable insights for stakeholders within the biopharmaceutical industry. Their core offerings include evidence review and synthesis, value evidence planning, health economic and decision modeling, and value communications. These services cater to a diverse clientele that encompasses global biopharmaceutical companies, regulatory bodies, healthcare payers, clinicians, and ultimately, patients.

By leveraging advanced AI technologies, Bridge Medical's solutions are designed to address challenges in accessing and utilizing innovative medicines throughout their lifecycle, thereby enhancing patient outcomes. The company operates across major global markets, including North America, Europe, and Asia-Pacific. Bridge Medical generates revenue primarily through partnerships and B2B transactions with large biopharmaceutical companies that require customized evidence solutions. Their business model focuses on providing comprehensive evidence services tailored to the specific needs of their clients, which often involves co-creating integrated evidence plans.

Each project results in a financial agreement based on the scope of work, with clients engaging in subscription-based services or project-based fees. These financial arrangements accommodate both single-project undertakings and ongoing contractual partnerships, with services related to health economic modeling and value communications representing critical components of the firm's revenue stream. In February 2026, Bridge Medical Consulting Ltd was acquired by Red Nucleus Solutions Limited Liability Company, enabling expansion of health economics and outcomes research capabilities. The acquisition supports biopharmaceutical companies in demonstrating clinical and economic value amidst growing regulatory and pricing scrutiny.

Future growth strategies include the development of new products aimed at enhancing evidence services and potential expansion into additional markets within Europe and Asia-Pacific by 2027.